With over 28 years of investment, consulting and entrepreneurial experience in the health care industry, Gerry has helped build life sciences companies at all stages of development. He focuses on investments in a range of therapeutic areas in the biotechnology and medical device sectors, including infectious diseases, neurology, cardiovascular disease, gene therapy and medical robotics. Gerry manages Lumira Ventures’ Boston office, which he established when he joined the firm in 2002.
Prior to joining Lumira Ventures, Gerry was an entrepreneur in the life sciences sector, founding and serving in a variety of management and board capacities at several venture capital-funded companies. Earlier in his career he was an engagement manager in the health care practice of The Boston Consulting Group, where he advised pharmaceutical and biotechnology firms on strategic issues including portfolio management, corporate partnering, R&D productivity, new product launches, disease management initiatives, acquisitions and post-merger integration. Gerry began his career as a member of the investment banking group of Credit Suisse First Boston in New York where his clients included public and private health care companies.
Industry Expertise (2)
Areas of Expertise (11)
Stanford University Graduate School of Business: M.B.A 1994
University of Virginia: B.A., Biology & Economics 1990
Selected Media Appearances (3)
HistoSonics, Non-Invasive Robotics Pioneer, Closes $54 Million Series C Financing
Cision PR Newswire online
"We believe that the HistoSonics platform offers a unique solution and significant promise to treat patients with a number of different diseases across global markets and care settings," commented Greg Sorensen, Vice President of Strategy and Business Development at Varian and new HistoSonics Board of Directors member. Also joining the company's Board as part of the financing are Gerry Brunk, Managing Director of Lumira Ventures, and an appointee from JJDC...
LICENSING & VENTURES GROUP HIRE SEED FUND DIRECTOR TO SHEPHERD UVA INNOVATIONS
University of Virginia News online
The fund will re-invest its gains to provide capital for additional investments. Investment decisions will be made with the oversight of the Investment Management Committee, which also led the search for the managing director. The committee comprises UVA alumni Gerry Brunk, managing director of Lumira Capital; Robert Paull, co-founder and venture partner of Lux Capital; Jonathan Ebinger, general partner of BlueRun Ventures; Dayna Grayson, partner of New Enterprise Associates; and Peter M. Grant II, partner at Anchormark Holdings LLC...
Engage Therapeutics Announces $23 Million Series A Financing to Advance Phase 2b Development of Novel Epileptic Seizure Rescue Therapy
Business Wire online
As part of the Series A financing, Heath Lukatch, Ph.D., Partner and Managing Director with TPG Biotech, Gerry Brunk, Managing Director at Lumira Capital, and Stephen Collins, President and CEO at Biscayne Neurotherapeutics will join the Company’s Board of Directors with Dr. Lukatch serving as Chairman. The Company’s existing board members are Greg Mayes; Warren Lammert, founder and CIO of Granite Point Capital and former Chairman of the Epilepsy Foundation; and Orrin Devinsky, M.D., director of the NYU Comprehensive Epilepsy Center...